Speaking at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Nathan Fowler, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the increasing need for biomarkers to identify a patients stage of disease, thus determining whether they are more likely to be cured in the future. Dr Fowler highlights that routine scans, currently used to monitor patients, are associated with a risk of radiation, and so in order to successfully identify a patients cure rate and likelihood to relapse, biomarkers are in need of development.
Are biomarkers the future in Non-Hodgkin Lymphoma?
